Loading
A phase 3 trial of Cediranib in Glioma & glioblastoma, run by AstraZeneca, completed.
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma is a phase 3 interventional study registered as NCT00777153 by AstraZeneca, with 423 participants recorded, started 2008-10 and reaching its primary completion in 2010-04. Interventions recorded: Cediranib, Cediranib, Lomustine Chemotherapy, Placebo Cediranib. Conditions recorded: Recurrent Glioblastoma.
Linked to the drug Cediranib because the registry names it among its interventions and Glioma & glioblastoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
423 enrolled.
IQR 80 to 128; Figures from the ClinicalTrials.gov results section (first posted 2012-12-21), not from a publication · IQR 83 to 201 · IQR 42 to 168
SourceIQR 4.1 to 14.5; Figures from the ClinicalTrials.gov results section (first posted 2012-12-21), not from a publication · IQR 6.2 to 14.5 · IQR 4.9 to NA
SourceThe full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares AstraZeneca, Glioma & glioblastoma and the tag pipeline.
Shares Cediranib, AstraZeneca and the tag pipeline.
Shares Cediranib and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/